Squarepoint’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.65M | Buy |
+29,281
| New | +$1.91M | ﹤0.01% | 2351 |
|
|
2025
Q4 | – | Sell |
-173,314
| Closed | -$8.45M | – | 4507 |
|
|
2025
Q3 | $8.45M | Buy |
+173,314
| New | +$10.7M | 0.01% | 1162 |
|
|
2025
Q2 | – | Sell |
-231,315
| Closed | -$14.7M | – | 4706 |
|
|
2025
Q1 | $14.7M | Buy |
231,315
+212,583
| +1,135% | +$14.5M | 0.02% | 836 |
|
|
2024
Q4 | $1.46M | Buy |
+18,732
| New | +$1.5M | ﹤0.01% | 2706 |
|
|
2024
Q3 | – | Sell |
-8,318
| Closed | -$688K | – | 4336 |
|
|
2024
Q2 | $688K | Sell |
8,318
-34,579
| -81% | -$3.04M | ﹤0.01% | 2838 |
|
|
2024
Q1 | $3.66M | Buy |
42,897
+31,440
| +274% | +$2.47M | 0.01% | 1680 |
|
|
2023
Q4 | $980K | Buy |
+11,457
| New | +$991K | ﹤0.01% | 2538 |
|
|
2022
Q2 | – | Sell |
-6,591
| Closed | -$417K | – | 3068 |
|
|
2022
Q1 | $417K | Sell |
6,591
-12,457
| -65% | -$677K | ﹤0.01% | 2109 |
|
|
2021
Q4 | $1.01M | Buy |
+19,048
| New | +$1.16M | ﹤0.01% | 1683 |
|
|
2021
Q3 | – | Sell |
-4,707
| Closed | -$314K | – | 3116 |
|
|
2021
Q2 | $314K | Sell |
4,707
-16,365
| -78% | -$1.16M | ﹤0.01% | 2491 |
|
|
2021
Q1 | $2.34M | Buy |
21,072
+11,574
| +122% | +$1.43M | 0.01% | 982 |
|
|
2020
Q4 | $1.13M | Sell |
9,498
-18,395
| -66% | -$1.98M | 0.01% | 1251 |
|
|
2020
Q3 | $2.43M | Sell |
27,893
-69,500
| -71% | -$6.07M | 0.03% | 566 |
|
|
2020
Q2 | $8.72M | Buy |
97,393
+55,768
| +134% | +$5.63M | 0.14% | 199 |
|
|
2020
Q1 | $4.15M | Buy |
41,625
+23,904
| +135% | +$2.59M | 0.11% | 239 |
|
|
2019
Q4 | $2.04M | Buy |
+17,721
| New | +$2.14M | 0.01% | 895 |
|
|
2019
Q3 | – | Sell |
-20,705
| Closed | -$2.49M | – | 2468 |
|
|
2019
Q2 | $2.49M | Buy |
+20,705
| New | +$2.04M | 0.02% | 720 |
|
|
2019
Q1 | – | Sell |
-2,029
| Closed | -$203K | – | 2262 |
|
|
2018
Q4 | $203K | Buy |
+2,029
| New | +$213K | ﹤0.01% | 1683 |
|
|
2018
Q3 | – | Sell |
-50,342
| Closed | -$4.51M | – | 2065 |
|
|
2018
Q2 | $4.51M | Buy |
+50,342
| New | +$4.25M | 0.06% | 426 |
|
|
2018
Q1 | – | Sell |
-3,526
| Closed | -$205K | – | 1863 |
|
|
2017
Q4 | $205K | Sell |
3,526
-11,228
| -76% | -$591K | ﹤0.01% | 1779 |
|
|
2017
Q3 | $662K | Buy |
+14,754
| New | +$613K | 0.01% | 870 |
|
Other funds holding HAE
VPM
VCM
RRAM
Squarepoint's HAE Position: Q1 2026 in Review
Squarepoint opened a new position in Haemonetics (HAE) in Q1 2026: 29,281 shares worth $1.65M. The stake represents ﹤0.01% of the portfolio and ranks #2351 among its holdings. This is a return to the name: Squarepoint previously reported a position in HAE as recently as Q3 2025.
Squarepoint first reported a position in HAE in Q3 2017 and has held it in 21 quarters since. The position peaked at $14.7M in Q1 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Squarepoint held 29,281 shares of Haemonetics worth $1.65M as of Q1 2026.
- Haemonetics was a new Squarepoint position in Q1 2026.
- Haemonetics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2351 holding.
- Squarepoint first reported a position in Haemonetics in Q3 2017 and has held it in 21 quarters since.
- Squarepoint's Haemonetics position peaked at $14.7M in Q1 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.